Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Ivabradine added to usual care in patients with heart failure: a systematic review with meta-analysis and trial sequential analysis

Publikation: Bidrag til tidsskriftReviewpeer review

DOI

  1. Was amorphous aluminium hydroxyphosphate sulfate adequately evaluated before authorisation in Europe?

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Methylphenidate for ADHD rejected from the WHO Essential Medicines List due to uncertainties in benefit-harm profile

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Blinding in randomised clinical trials of psychological interventions: a retrospective study of published trial reports

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Trial Sequential Analysis in Critical Care Medicine: The Way Forward

    Publikation: Bidrag til tidsskriftLetterpeer review

  2. Liver support systems for adults with acute-on-chronic liver failure

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Speed of cooling after cardiac arrest in relation to the intervention effect: a sub-study from the TTM2-trial

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

OBJECTIVES: To assess the beneficial and harmful effects of adding ivabradine to usual care in participants with heart failure.

DESIGN: A systematic review with meta-analysis and trial sequential analysis.

ELIGIBILITY CRITERIA: Randomised clinical trials comparing ivabradine and usual care with usual care (with or without) placebo in participants with heart failure.

INFORMATION SOURCES: Medline, Embase, CENTRAL, LILACS, CNKI, VIP and other databases and trial registries up until 31 May 2021.

DATA EXTRACTION: Primary outcomes were all-cause mortality, serious adverse events and quality of life. Secondary outcomes were cardiovascular mortality, myocardial infarction and non-serious adverse events. We performed meta-analysis of all outcomes. We used trial sequential analysis to control risks of random errors, the Cochrane risk of bias tool to assess the risks of systematic errors and the Grading of Recommendations Assessment, Development and Evaluation (GRADE) to assess the certainty of the evidence.

RESULTS: We included 109 randomised clinical trials with 26 567 participants. Two trials were at low risk of bias, although both trials were sponsored by the company that developed ivabradine. All other trials were at high risk of bias. Meta-analyses and trial sequential analyses showed that we could reject that ivabradine versus control reduced all-cause mortality (risk ratio (RR)=0.94; 95% CI 0.88 to 1.01; p=0.09; high certainty of evidence). Meta-analysis and trial sequential analysis showed that ivabradine seemed to reduce the risk of serious adverse events (RR=0.90; 95% CI 0.87 to 0.94; p<0.00001; number needed to treat (NNT)=26.2; low certainty of evidence). This was primarily due to a decrease in the risk of 'cardiac failure' (RR=0.83; 95% CI 0.71 to 0.97; p=0.02; NNT=43.9), 'hospitalisations' (RR=0.89; 95% CI 0.85 to 0.94; p<0.0001; NNT=36.4) and 'ventricular tachycardia' (RR=0.59; 95% CI 0.43 to 0.82; p=0.001; NNT=212.8). However, the trials did not describe how these outcomes were defined and assessed during follow-up. Meta-analyses showed that ivabradine increased the risk of atrial fibrillation (RR=1.19; 95% CI 1.04 to 1.35; p=0.008; number needed to harm (NNH)=116.3) and bradycardia (RR=3.95; 95% CI 1.88 to 8.29; p=0.0003; NNH=303). Ivabradine seemed to increase quality of life on the Kansas City Cardiomyopathy Questionnaire (KCCQ) (mean difference (MD)=2.92; 95% CI 1.34 to 4.50; p=0.0003; low certainty of evidence), but the effect size was small and possibly without relevance to patients, and on the Minnesota Living With Heart Failure Questionnaire (MLWHFQ) (MD=-5.28; 95% CI -6.60 to -3.96; p<0.00001; very low certainty of evidence), but the effects were uncertain. Meta-analysis showed no evidence of a difference between ivabradine and control when assessing cardiovascular mortality and myocardial infarction. Ivabradine seemed to increase the risk of non-serious adverse events.

CONCLUSION AND RELEVANCE: High certainty evidence shows that ivabradine does not seem to affect the risks of all-cause mortality and cardiovascular mortality. The effects on quality of life were small and possibly without relevance to patients on the KCCQ and were very uncertain for the MLWHFQ. The effects on serious adverse events, myocardial infarction and hospitalisation are uncertain. Ivabradine seems to increase the risk of atrial fibrillation, bradycardia and non-serious adverse events.PROSPERO registration number: CRD42018112082.

OriginalsprogEngelsk
TidsskriftBMJ Evidence-Based Medicine
Vol/bind27
Udgave nummer4
Sider (fra-til)224-234
Antal sider11
ISSN1356-5524
DOI
StatusUdgivet - aug. 2022

Bibliografisk note

© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

ID: 70263287